Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,666 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3-/- mice transplanted with human PBMCs.
Ogata-Aoki H, Higashi-Kuwata N, Hattori SI, Hayashi H, Danish M, Aoki M, Shiotsu C, Hashiguchi Y, Hamada A, Kobayashi H, Ihn H, Okada S, Mitsuya H. Ogata-Aoki H, et al. Among authors: aoki m. Antiviral Res. 2018 Jan;149:78-88. doi: 10.1016/j.antiviral.2017.09.003. Epub 2017 Sep 8. Antiviral Res. 2018. PMID: 28893602 Free PMC article.
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H. Aoki M, et al. Among authors: aoki ogata h. J Virol. 2009 Apr;83(7):3059-68. doi: 10.1128/JVI.02539-08. Epub 2009 Jan 28. J Virol. 2009. PMID: 19176623 Free PMC article.
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Tojo Y, Koh Y, Amano M, Aoki M, Das D, Kulkarni S, Anderson DD, Ghosh AK, Mitsuya H. Tojo Y, et al. Among authors: aoki m. Antimicrob Agents Chemother. 2010 Aug;54(8):3460-70. doi: 10.1128/AAC.01766-09. Epub 2010 May 3. Antimicrob Agents Chemother. 2010. PMID: 20439612 Free PMC article.
Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. Ide K, et al. Among authors: aoki m. Antimicrob Agents Chemother. 2011 Apr;55(4):1717-27. doi: 10.1128/AAC.01540-10. Epub 2011 Jan 31. Antimicrob Agents Chemother. 2011. PMID: 21282450 Free PMC article.
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H. Amano M, et al. Among authors: aoki m. Antimicrob Agents Chemother. 2013 May;57(5):2036-46. doi: 10.1128/AAC.02189-12. Epub 2013 Feb 12. Antimicrob Agents Chemother. 2013. PMID: 23403426 Free PMC article.
P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H. Yedidi RS, et al. Among authors: aoki m. Antimicrob Agents Chemother. 2013 Oct;57(10):4920-7. doi: 10.1128/AAC.00868-13. Epub 2013 Jul 22. Antimicrob Agents Chemother. 2013. PMID: 23877703 Free PMC article.
3,666 results